Cargando…
Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment
BACKGROUND: Rituximab has been widely used in many autoimmune diseases. AIM: To evaluate the infection risk of rituximab in autoimmune hematological disorders. METHODS: Retrospectively studied and compared the clinical data of 89 patients in our hospital who used low‐dose rituximab (group R) or puls...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595891/ https://www.ncbi.nlm.nih.gov/pubmed/32794271 http://dx.doi.org/10.1002/jcla.23455 |
_version_ | 1783601983583682560 |
---|---|
author | Wang, Honglei Yan, Siyang Liu, Hui Li, Lijuan Song, Jia Wang, Guojin Wang, Huaquan Wu, Yuhong Shao, Zonghong Fu, Rong |
author_facet | Wang, Honglei Yan, Siyang Liu, Hui Li, Lijuan Song, Jia Wang, Guojin Wang, Huaquan Wu, Yuhong Shao, Zonghong Fu, Rong |
author_sort | Wang, Honglei |
collection | PubMed |
description | BACKGROUND: Rituximab has been widely used in many autoimmune diseases. AIM: To evaluate the infection risk of rituximab in autoimmune hematological disorders. METHODS: Retrospectively studied and compared the clinical data of 89 patients in our hospital who used low‐dose rituximab (group R) or pulse cyclophosphamide (group C) for their refractory/relapsed autoimmune hematological diseases from January 2011 to January 2017. The kinds of their diseases included autoimmune hemolytic disease (AIHA), Evans syndrome, and idiopathic thrombocytopenic purpura (ITP). All patients chose either rituximab treatment or cyclophosphamide treatment on their own considerations. FINDINGS: The median follow‐up time was six months in group R and four months in group C. After treatments, the patients in group R showed higher white blood cell (WBC) count and neutrophil count than group C (P = .020, P = .037). CD20‐positive B cells in group R remained at a very low level after rituximab treatment and need about 15 months to return to normal level, which was longer than group C (six months). The incidence of infection in these two groups has no significant difference, which was 34.7% (17/30) in group R and 32.5% (13/28) in group C (P = .976). Tuberculosis infections after rituximab treatment were found in three patients for the first time. CONCLUSION: The G‐CSF, nadir WBC count, and IgA level were protective factors of infection during rituximab treatment. Low‐dose rituximab therapy in autoimmune hematological diseases does not increase infection risk compared with cyclophosphamide. |
format | Online Article Text |
id | pubmed-7595891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75958912020-11-02 Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment Wang, Honglei Yan, Siyang Liu, Hui Li, Lijuan Song, Jia Wang, Guojin Wang, Huaquan Wu, Yuhong Shao, Zonghong Fu, Rong J Clin Lab Anal Research Articles BACKGROUND: Rituximab has been widely used in many autoimmune diseases. AIM: To evaluate the infection risk of rituximab in autoimmune hematological disorders. METHODS: Retrospectively studied and compared the clinical data of 89 patients in our hospital who used low‐dose rituximab (group R) or pulse cyclophosphamide (group C) for their refractory/relapsed autoimmune hematological diseases from January 2011 to January 2017. The kinds of their diseases included autoimmune hemolytic disease (AIHA), Evans syndrome, and idiopathic thrombocytopenic purpura (ITP). All patients chose either rituximab treatment or cyclophosphamide treatment on their own considerations. FINDINGS: The median follow‐up time was six months in group R and four months in group C. After treatments, the patients in group R showed higher white blood cell (WBC) count and neutrophil count than group C (P = .020, P = .037). CD20‐positive B cells in group R remained at a very low level after rituximab treatment and need about 15 months to return to normal level, which was longer than group C (six months). The incidence of infection in these two groups has no significant difference, which was 34.7% (17/30) in group R and 32.5% (13/28) in group C (P = .976). Tuberculosis infections after rituximab treatment were found in three patients for the first time. CONCLUSION: The G‐CSF, nadir WBC count, and IgA level were protective factors of infection during rituximab treatment. Low‐dose rituximab therapy in autoimmune hematological diseases does not increase infection risk compared with cyclophosphamide. John Wiley and Sons Inc. 2020-08-13 /pmc/articles/PMC7595891/ /pubmed/32794271 http://dx.doi.org/10.1002/jcla.23455 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Wang, Honglei Yan, Siyang Liu, Hui Li, Lijuan Song, Jia Wang, Guojin Wang, Huaquan Wu, Yuhong Shao, Zonghong Fu, Rong Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
title | Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
title_full | Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
title_fullStr | Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
title_full_unstemmed | Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
title_short | Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
title_sort | infection risk in autoimmune hematological disorders with low‐dose rituximab treatment |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595891/ https://www.ncbi.nlm.nih.gov/pubmed/32794271 http://dx.doi.org/10.1002/jcla.23455 |
work_keys_str_mv | AT wanghonglei infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT yansiyang infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT liuhui infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT lilijuan infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT songjia infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT wangguojin infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT wanghuaquan infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT wuyuhong infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT shaozonghong infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment AT furong infectionriskinautoimmunehematologicaldisorderswithlowdoserituximabtreatment |